Sign In
Buy AMPH
$18.12
-0.330 (-1.79%)
At Close: Jun 03, 2026
Agreement expands Amphastar's proprietary peptide pipeline into broader inflammatory and autoimmune conditions RANCHO CUCAMONGA, CA / ACCESS Newswire / January 12, 2026 / Amphastar Pharmaceuticals, In
Amphastar Pharmaceuticals to Present at the J.P. Morgan 2026 Healthcare Conference
06:00am, Wednesday, 07'th Jan 2026
RANCHO CUCAMONGA, CA / ACCESS Newswire / January 7, 2026 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at
Amphastar Director Sells 16,679 Shares for $441,800
09:47am, Tuesday, 23'rd Dec 2025
Floyd Petersen exercised and sold 16,679 shares of Amphastar in November, pocketing more than $441,000. He still retains about $2 million worth of shares.
Amphastar Announces FDA Approval for Teriparatide Injection
06:00am, Monday, 15'th Dec 2025
RANCHO CUCAMONGA, CA / ACCESS Newswire / December 15, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbre
Capital Fund Management S.A. Takes $931,000 Position in Amphastar Pharmaceuticals, Inc. $AMPH
04:00am, Saturday, 06'th Dec 2025
Capital Fund Management S.A. acquired a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) in the undefined quarter, according to its most recent filing with the Securities and Exchange Co
Amphastar Pharmaceuticals to Present at the 37th Annual Piper Sandler Healthcare Conference
06:00am, Monday, 24'th Nov 2025
RANCHO CUCAMONGA, CA / ACCESS Newswire / November 24, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Tony Marrs, EVP of Regulatory Affairs and Clinical
Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
06:00am, Wednesday, 12'th Nov 2025
RANCHO CUCAMONGA, CA / ACCESS Newswire / November 12, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration
Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2025 Earnings Call Transcript
12:16pm, Saturday, 08'th Nov 2025
Amphastar Pharmaceuticals, Inc. ( AMPH ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Dan Dischner - Senior Vice President of Human Resources & Corporate Communication Willi
Here's What Key Metrics Tell Us About Amphastar (AMPH) Q3 Earnings
07:31pm, Thursday, 06'th Nov 2025
The headline numbers for Amphastar (AMPH) give insight into how the company performed in the quarter ended September 2025, but it may be worthwhile to compare some of its key metrics to Wall Street es
Amphastar Pharmaceuticals (AMPH) Q3 Earnings and Revenues Top Estimates
06:56pm, Thursday, 06'th Nov 2025
Amphastar Pharmaceuticals (AMPH) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.77 per share. This compares to earnings of $0.96 per share a year ago.
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2025
04:05pm, Thursday, 06'th Nov 2025
Reports Net Revenues of $191.8 million for the Three Months Ended September 30, 2025 GAAP net income of $17.4 million, or $0.37 per share, for the third quarter Adjusted non-GAAP net income of $44.7 m
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for
11:07am, Thursday, 30'th Oct 2025
Amphastar (AMPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 6th, 2025
06:00am, Monday, 27'th Oct 2025
RANCHO CUCAMONGA, CA / ACCESS Newswire / October 27, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its third quarter of 2025 ended September
IFP Advisors Inc Buys 877 Shares of Amphastar Pharmaceuticals, Inc. $AMPH
03:07am, Wednesday, 22'nd Oct 2025
IFP Advisors Inc increased its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) by 75.7% during the undefined quarter, according to its most recent disclosure with the SEC. The instit
Analyzing Amphastar Pharmaceuticals (NASDAQ:AMPH) and Teva Pharmaceutical Industries (NYSE:TEVA)
01:48am, Wednesday, 22'nd Oct 2025
Amphastar Pharmaceuticals (NASDAQ: AMPH - Get Free Report) and Teva Pharmaceutical Industries (NYSE: TEVA - Get Free Report) are both medical companies, but which is the superior investment? We will c
